SCHEMBL7185600

SCHEMBL7185600

CC(C)(C)c1cc(C(C)(C)C)c(C(=O)c2ccccc2[P](=O)C(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c(C(C)(C)C)c1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
TAS2R14 Q9NYV8 1/20 0.33
PTGES O14684 1/20 0.32
ALOX5 P09917 1/20 0.32
PTGS2 P35354 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
RECQL P46063 1/20 0.32
KCNK3 O14649 2/20 0.32
KCNK9 Q9NPC2 2/20 0.32
PTGS1 P23219 1/20 0.32
ACHE P22303 1/20 0.32
RORC P51449 2/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
F2R P25116 1/20 0.32
RORB Q92753 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7181486 0.87 TP53 (0.36) SMN1; SMN2ALOX5PTGS2CYP3A4CYP2C9
SCHEMBL7182631 0.86 RORB (0.37) LMNAGAAALOX5PTGS2RECQL
SCHEMBL7185498 0.84 MAPT (0.39) LMNARXFP1KCNK3KCNK9RORC
SCHEMBL7189850 0.84 MEN1 (0.34) SMN1; SMN2LMNAALOX5PTGS2
SCHEMBL7180621 0.83 TAS2R14 (0.38) LMNAGAATAS2R14KCNK3KCNK9
SCHEMBL7188665 0.82 MEN1 (0.38) SMN1; SMN2LMNAGAATAS2R14RECQL
SCHEMBL7189056 0.82 ALOX5 (0.31) SMN1; SMN2ALOX5PTGS2
SCHEMBL7181426 0.82 TAS2R14 (0.41) LMNAGAATAS2R14RECQLKCNK3
SCHEMBL7175306 0.82 TAS2R14 (0.39) LMNAGAATAS2R14KCNK3KCNK9
SCHEMBL7186793 0.81 KCNK3 (0.37) SMN1; SMN2LMNAGAATAS2R14RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SMN1; SMN2 2939/4885LMNA 3241/4885GAA 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.